Recursion Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is a clinical-stage TechBio company that integrates automation, high-throughput wet-lab biology, and machine learning to industrialize and accelerate drug discovery. Operating through its proprietary Recursion Operating System (OS), the company generates massive biological and chemical datasets to train machine learning models, mapping complex cellular morphology and genetic perturbations. Recursion's business model balances a pipeline of wholly owned precision therapies in oncology and rare diseases with high-value strategic partnerships with global pharmaceutical leaders like Roche, Genentech, and Sanofi.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Integrating Exscientia's precision chemistry platform (Centaur) with the Recursion OS to create a vertically integrated, full-stack drug discovery engine.
Expected impact: Aims to reduce compounds synthesized by approximately 90% compared to industry averages and accelerate candidate discovery timelines by roughly 2x.
Consolidating the internal pipeline to 5 clinical programs and approximately 15 discovery programs while deprioritizing non-core programs to moderate cash burn.
Expected impact: Preserves cash runway into early 2028 by keeping 2026 cash operating expenses under $390 million.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To combine Recursion's scaled biology exploration and translational expertise with Exscientia's precision chemistry design and automated synthesis, creating a full-stack technology-enabled drug discovery platform.
Financial impact: Added over 20 programs to the portfolio, increased the total milestone opportunity to more than $20 billion, and expected to achieve annual synergies exceeding $100 million.
Acquiring Rallybio's remaining 50% interest in the ENPP1 joint venture to take sole responsibility for pushing the REV102 program (an ENPP1 inhibitor for hypophosphatasia) toward human clinical testing.
Financial impact: Upfront consideration of $7.5 million in Class A common stock, with up to $12.5 million in contingent milestone equity payments and a $5 million clinical milestone payment, plus low single-digit royalties on future net sales.
Strategic Partnerships
High; leverages Recursion OS to discover, design, and advance up to 15 small molecule programs across oncology and immunology.
Terms: Recursion has received $134 million in upfront and progress-based milestones to date (including a $4 million milestone in February 2026), with potential for over $300 million in milestones per program plus royalties.
High; utilizes Recursion OS to map complex biology and identify novel targets in neuroscience and a gastrointestinal oncology indication.
Terms: Recursion received a $150 million upfront payment and has earned $213 million in total cash inflows to date (including a $30 million milestone in late 2025), with potential for over $300 million in milestones per program across up to 40 programs, plus tiered royalties.
Medium; leverages Bayer's small molecule library and Recursion's AI platform to identify novel therapeutic targets for challenging oncology indications.
Terms: Recursion is eligible to receive up to $1.5 billion in potential development and commercial milestone payments across up to seven oncology programs, plus royalties on net sales.
Medium; utilizes Recursion's AI platform to discover novel small molecule drug candidates across oncology, neuroinflammation, and immunology.
Terms: Recursion received a $20.1 million non-refundable upfront payment and is eligible for additional performance-based milestone payments.